miércoles, 21 de junio de 2017

New blog post from FDA Commissioner, Dr. Scott Gottlieb, on how FDA is working to lift barriers to generic drug competition- Drug Information Update

FDA Working to Lift Barriers to Generic Drug Competition | FDA Voice



FDA Logo, hands holding pills
The Division of Drug Information (DDI)- serving the public by providing information on human drug products and drug product regulation by FDA.


Too many patients are being priced out of the medicines they need. While FDA doesn’t have a direct role in drug pricing, we can take steps to help address this problem by facilitating increased competition in the market for prescription drugs through the approval of lower-cost, generic medicines.
Over the last decade alone, competition from safe and effective generic drugs has saved the health care system about $1.67 trillion. When generics are dispensed at the pharmacy, the immediate savings to each of us are clear. We could see even greater cost savings if we helped more safe and effective generic drugs get to market sooner, after patent and statutory exclusivity periods have lapsed, by addressing some of the scientific and regulatory obstacles to generic competition across the full range of FDA-approved drugs. These barriers may delay and, in some cases, ultimately deny patient access to more affordable drugs.
That’s why we’re working on a Drug Competition Action Plan. As part of this effort, today, we’re announcing in the  Federal Register our intent to hold a public meeting on July 18, 2017, to solicit input on places where FDA’s rules – including the standards and procedures related to generic drug approvals – are being used in ways that may create obstacles to generic access, instead of ensuring the vigorous competition Congress intended.
To read the full blog, please visit: Drug Competition Action Plan

No hay comentarios:

Publicar un comentario